Incidence and risk factors of serious infection in neuromyelitis optica spectrum disorders (NMOSD) patients: a retrospective cohort study using Medical Data Vision (MDV) database
Not Applicable
- Conditions
- euromyelitis optica spectrum disorders (NMOSD)
- Registration Number
- JPRN-UMIN000051151
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 4000
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who have any record of prescription for the following drugs for the treatment of multiple sclerosis (MS) at any time point: - Interferon beta-1a, - Interferon beta-1b, - Ofatumumab, - Natalizumab, - Glatiramer acetate, - Dimethyl fumarate, - Siponimod fumarate, - Fingolimod hydrochloride.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rate, proportion, frequency, cumulative incidence, cumulative mean count of serious infections
- Secondary Outcome Measures
Name Time Method Hazard ratios of potential risk factors for serious infections